Helge Lubenow - Qiagen NV President
| QGEN Stock | USD 42.98 0.30 0.70% |
President
Dr. Helge Lubenow is Senior Vice President Molecular Diagnostics Business Area of Qiagen NV. She joined QIAGEN in 1997 as a scientist in the instruments division and held progressively more senior management positions in Research and Development and Marketing. From 2008 until 2010 Dr. Lubenow was based in Australia and served as Vice President Operations Automated Systems leading the integration and further development of QIAGENs realtime PCR platform an integral part of the revolutionary QIAsymphony RGQ system. In 2011 she was named Vice President Molecular Diagnostics Business and in 2012 she was named Senior Vice President to lead the Molecular Diagnostics Business Area since 2012.
| Tenure | 12 years |
| Professional Marks | Ph.D |
| Address | Hulsterweg 82, Venlo, Netherlands, 5912 PL |
| Phone | 31 77 355 6600 |
| Web | https://www.qiagen.com |
Qiagen NV Management Efficiency
The company has return on total asset (ROA) of 0.0456 % which means that it generated a profit of $0.0456 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0941 %, meaning that it created $0.0941 on every $100 dollars invested by stockholders. Qiagen NV's management efficiency ratios could be used to measure how well Qiagen NV manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Qiagen NV's Return On Capital Employed is very stable compared to the past year. As of the 4th of May 2024, Return On Assets is likely to grow to 0.06, while Return On Tangible Assets are likely to drop 0.09. At this time, Qiagen NV's Other Current Assets are very stable compared to the past year. As of the 4th of May 2024, Total Current Assets is likely to grow to about 2.3 B, while Total Assets are likely to drop about 3.2 B.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Matthew Gugino | Danaher | N/A | |
| Patrick Kaltenbach | Agilent Technologies | 53 | |
| Omead Ostadan | Illumina | 46 | |
| Paul Bianchi | Illumina | 53 | |
| Daniel Comas | Danaher | 55 | |
| Jacquie Ross | Illumina | N/A | |
| Matthew McGrew | Danaher | 52 | |
| Nicholas Naclerio | Illumina | 53 | |
| Charles Dadswell | Illumina | 65 | |
| John Lynch | Waters | N/A | |
| William King | Danaher | 53 | |
| Mostafa Ronaghi | Illumina | 49 | |
| Michel Lagarde | Thermo Fisher Scientific | 49 | |
| William Daniel | Danaher | 53 | |
| Mark Beaudouin | Waters | 63 | |
| Alan Malus | Thermo Fisher Scientific | 55 | |
| Daniel Raskas | Danaher | 54 | |
| Karen McGinnis | Illumina | 50 | |
| Thomas Loewald | Thermo Fisher Scientific | 52 | |
| Robert McMahon | Agilent Technologies | 55 | |
| Patrick Durbin | Thermo Fisher Scientific | 51 | |
Management Performance
| Return On Equity | 0.0941 | ||||
| Return On Asset | 0.0456 |
Qiagen NV Leadership Team
Elected by the shareholders, the Qiagen NV's board of directors comprises two types of representatives: Qiagen NV inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Qiagen. The board's role is to monitor Qiagen NV's management team and ensure that shareholders' interests are well served. Qiagen NV's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Qiagen NV's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Annette Koch, Senior Vice President and Chief Human Resources Officer, Member of the Executive Committee | ||
| Stephane Bancel, Independent Member of the Supervisory Board | ||
| Peer Schatz, CEO and Managing Director | ||
| JeanPascal Viola, Senior Area | ||
| Elaine Mardis, Independent Member of the Supervisory Board | ||
| Roland Sackers, Managing Director, Chief Financial Officer, Member of the Executive Committee | ||
| Stephany Foster, Senior Resources | ||
| Thomas Theuringer, Director Communications | ||
| Brad Crutchfield, Senior Vice President - Life Sciences Business Area | ||
| Antonio Santos, Senior Operations | ||
| Dietrich Hauffe, Senior Vice President - Life Sciences Business Area | ||
| Barthold Piening, Senior Vice President Head of Global Operations, Member of the Executive Committee | ||
| Laura Furmanski, Senior Vice President - Bioinformatics Business Area | ||
| Thierry Bernard, Chief Executive Officer, Managing Director, Member of the Executive Board | ||
| Toralf Haag, Independent Member of the Supervisory Board | ||
| Thomas Schweins, Senior Vice President - Human Resources, Strategy & Marketing Services | ||
| Douglas Liu, Sr. VP of Global Operations | ||
| Manuel Mendez, Senior Vice President - Global Commercial Operations | ||
| Manfred Karobath, Independent Supervisory Director | ||
| Benedikt Braunmuehl, Senior Vice President - Global Commercial Operations | ||
| Helge Lubenow, Senior Vice President - Molecular Diagnostics Business Area | ||
| John Gilardi, VP of Corporate Communications and Investor Relations | ||
| Hakan Bjorklund, Supervisory Board Director | ||
| Jonathan Sheldon, Senior Vice President Member of the Executive Committee | ||
| Mark Gladwell, Senior Vice President Global Operations, Member of the Executive Committee | ||
| Thomas Ebeling, Independent Member of the Supervisory Board | ||
| Elizabeth Tallett, Independent Member of the Supervisory Board | ||
| Thomas Neidert, Vice Treasury | ||
| Metin Colpan, Co-Founder, Supervisory Director and Chairman of Science and Technology Committee | ||
| Werner Brandt, Independent Supervisory Director | ||
| Ulrich Schriek, Senior Vice President - Corporate Business Development | ||
| Ross Levine, Independent Member of the Supervisory Board | ||
| Lawrence Rosen, Independent Chairman of the Supervisory Board |
Qiagen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Qiagen NV a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0941 | ||||
| Return On Asset | 0.0456 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 10.08 B | ||||
| Shares Outstanding | 221.85 M | ||||
| Shares Owned By Insiders | 0.41 % | ||||
| Shares Owned By Institutions | 73.97 % | ||||
| Number Of Shares Shorted | 2.96 M | ||||
| Price To Earning | 24.32 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Qiagen NV using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Qiagen NV. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. To learn how to invest in Qiagen Stock, please use our How to Invest in Qiagen NV guide.Note that the Qiagen NV information on this page should be used as a complementary analysis to other Qiagen NV's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Complementary Tools for Qiagen Stock analysis
When running Qiagen NV's price analysis, check to measure Qiagen NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Qiagen NV is operating at the current time. Most of Qiagen NV's value examination focuses on studying past and present price action to predict the probability of Qiagen NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Qiagen NV's price. Additionally, you may evaluate how the addition of Qiagen NV to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is Qiagen NV's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Qiagen NV. If investors know Qiagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Qiagen NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.07) | Earnings Share 1.52 | Revenue Per Share 8.732 | Quarterly Revenue Growth (0.06) | Return On Assets 0.0456 |
The market value of Qiagen NV is measured differently than its book value, which is the value of Qiagen that is recorded on the company's balance sheet. Investors also form their own opinion of Qiagen NV's value that differs from its market value or its book value, called intrinsic value, which is Qiagen NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Qiagen NV's market value can be influenced by many factors that don't directly affect Qiagen NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Qiagen NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if Qiagen NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Qiagen NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.